Interim report, foreign filer
Open the filing on sec.gov
Bright Minds Biosciences Inc. (DRUG)
Nasdaq: DRUG · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2020
The companyfiscal 2024, as filed
Revenuen/a
Net income-C$2.8M+62.0%
Earnings per shareC$-0.65+67.2%
Operating cash flow-C$1.9M+73.7%
CashC$5.7M-15.2%
Debtn/a
Shareholders’ equityC$5.5M-16.1%
Shares, diluted4,310,168+15.9%
Return on equity-50.6%
The recordfrom its filings
Filings in 202634
Newest filingNov 2 · 6-K
Annual reportDec 23, 2025
Quarterly reportn/a
Next report due40-F by Jan 28
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted0
Filer category<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in CAD. Nothing here is a forecast.
News
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Employee stock plan registration
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Activist holder update, amended
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.